PCA062 in pCAD-positive Tumors.
Public ClinicalTrials.gov record NCT02375958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A first-in-human sttudy using PCA062 in patients with p-CAD positive solid tumors.
Study identification
- NCT ID
- NCT02375958
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 47 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2015
- Primary completion
- Jul 16, 2018
- Completion
- Jul 16, 2018
- Last update posted
- Dec 18, 2020
2015 – 2018
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
Recently updated Triple Negative Breast Cancer trials
Other public records listing Triple Negative Breast Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT03401385: First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) Active, not recruiting
- NCT06577987: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting
- NCT07768436: A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer Recruiting
- NCT07038369: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations Active, not recruiting
- NCT04230109: Sacituzumab Govitecan In TNBC Recruiting
- NCT07672431: Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02375958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2020 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02375958 live on ClinicalTrials.gov.